drugset / Trial / NCT04370288

Clinical Application of Methylene Blue for Treatment of Covid-19 Patients

NCT04370288

Phase 1 Unknown 20 enrolled Mashhad University of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment

Summary

The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event. Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized form, blue color) has been used in many different areas of clinical medicine, ranging from malaria to orthopedics. Leucomethylene Blue (reduced form of MB, colorless) may be applied for the treatment of COVID-19 according to the scientific evidences.

Timeline

Start
2020-04-19
Primary completion
2020-09-20
Completion
2020-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent Other
Subject N-acetylcysteine Small molecule Other
Subject Vitamin C Other / unclassified Other

Indications